ArticleFrontiers in oncology2026
From proteome-wide Mendelian randomization and multi-omics integration to functional validation: TGFB3 as a prioritized candidate in gastric adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric adenocarcinoma lacks robust circulating biomarkers and tractable targets. We assessed whether genetically predicted plasma protein levels influence disease risk and sought druggable candidates using a proteome-wide Mendelian randomization (MR) framework. Methods: We integrated deCODE plasma protein quantitative trait loci (pQTLs) with gastric cancer GWAS in a proteome-wide two-sample MR framework to identify circulating proteins causally associated with gastric cancer. Protein-protein interaction topology was used to prioritize eight hub proteins, which were further evaluated in an eight-gene artificial neural network (ANN) classifier. Single-cell and spatial transcriptomics, together with multiplex immunofluorescence, mapped hub-gene expression across tumor, stromal and immune compartments. Finally, we focused on TGFB3 as a genetically and spatially prioritized target, combining in silico ligand screening with Results: Proteome-wide MR highlighted 29 circulating proteins with putative causal effects on gastric cancer, of which eight (ERBB3, LGR4, BMP4, CD248, MGP, TGFB3, GRP and ETS2) occupied central positions in the interaction network. The corresponding eight-gene ANN showed robust discrimination between gastric cancer and non-tumor tissue across multiple cohorts and improved diagnostic performance beyond clinical variables. Single-cell, spatial and multiplex immunofluorescence analyses localized these hubs to epithelial, fibroblast and endothelial compartments, with TGFB3 enriched at tumor-stroma interfaces and associated with poor survival. Virtual screening nominated TGFB3-binding ligands and proflavine hemisulfate formed a stable complex with TGFB3 in silico while attenuating TGFB3-driven proliferation, migration and PI3K-dependent survival signaling in AGS cells. Conclusion: Our proteome-wide MR framework identifies genetically supported circulating proteins that contribute to gastric carcinogenesis and converges on TGFB3 as a tractable stromal signaling axis. Proflavine hemisulfate functions as a mechanistically informative chemical probe of TGFB3-PI3K survival signaling in gastric cancer cells, providing a starting scaffold for future TGFB3-targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.